Methotrexat Stada (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This inhibition reduces the synthesis of nucleotides needed for DNA and RNA production, limiting the proliferation of rapidly dividing cells. Additionally, it increases extracellular adenosine, which suppresses inflammatory pathways, providing both anticancer and immunosuppressive benefits.

The dose of Methotrexat Stada is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Dosing regimens can vary widely, ranging from low weekly doses for autoimmune diseases to higher, more intensive schedules for oncologic protocols. Always follow the prescriber’s instructions.

Methotrexat Stada is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended during breastfeeding, as it can be excreted in milk and potentially harm the infant. Women of child‑bearing potential must use effective contraception while on therapy.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming eligibility, then responding with pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Methotrexat Stada belongs to the antimetabolite class, similar to drugs like azathioprine or leflunomide for autoimmune diseases, and to other chemotherapy agents such as cyclophosphamide for cancers. Compared with leflunomide, methotrexate has a longer history of use in rheumatoid arthritis and may offer stronger anti‑inflammatory effects, but it also carries a higher risk of hepatic and hematologic toxicity, requiring more frequent monitoring.

Methotrexat Stada must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product is temporarily removed from refrigeration, it should be returned to the controlled temperature zone within the time limits specified by the manufacturer to maintain potency.

Methotrexat Stada is supplied as an injectable solution for intramuscular or subcutaneous administration. The injection is typically given once weekly, although the exact schedule is determined by the prescriber. Proper aseptic technique is essential, and the injection site should be rotated to reduce local irritation. Patients may be instructed on self‑administration after appropriate training.

The most serious risks include severe liver toxicity that can progress to fibrosis or cirrhosis, bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis causing respiratory compromise, and life‑threatening infections due to immunosuppression. Renal failure and rare anaphylactic reactions are also critical concerns. Early detection through regular laboratory monitoring is essential to mitigate these risks.

Methotrexat Stada is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate or its excipients, patients with severe hepatic impairment, significant renal dysfunction, active uncontrolled infections, and those with pre‑existing pulmonary disease that could be exacerbated. Clinicians should also exercise caution in patients with a history of alcohol abuse or concurrent use of other myelosuppressive agents.